AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17332184 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood lead concentration at 7 years of age
Number of subjects: 780
Study 17332184 — intervention group
Group type: COMPARATOR
Intervention: Blood lead concentration at 2 years of age
Number of subjects: 780
Study 15351854 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant urokinase (r-UK) 5000 IU/ml
Number of subjects: 180
Study 15351854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 12359410 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study 12359410 — intervention group
Group type: COMPARATOR
Intervention: Carotid angioplasty and stent (CAS)
Number of subjects: 0
Study 9684393 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily buprenorphine (8 mg)
Number of subjects: 11
Study 9684393 — intervention group
Group type: COMPARATOR
Intervention: Alternate-day dosing of buprenorphine and placebo
Number of subjects: 11
Study 9684393 — intervention group
Group type: COMPARATOR
Intervention: Placebo (days 37 to 52)
Number of subjects: 11
Study 7525794 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 6
Study 7525794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2547138 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg piperazine oestrone sulphate
Number of subjects: 7
Study 2547138 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg piperazine oestrone sulphate + 5.0 mg oestriol
Number of subjects: 7
Study 2547138 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg oestradiol valerate
Number of subjects: 7
Study 2547138 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.0 mg oestriol
Number of subjects: 7
Study 2547138 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination with 250 micrograms of levonorgestrel
Number of subjects: 7
Study 2547138 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration for a week
Number of subjects: 7
Study 2547138 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen D (10.0 mg oestriol)
Number of subjects: 7
Study 2547138 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimens A (2.5 mg piperazine oestrone sulphate) and B (1.25 mg piperazine oestrone sulphate + 5.0 mg oestriol)
Number of subjects: 7
Study 2547138 — intervention group
Group type: EXPERIMENTAL
Intervention: All oestrogen formulations
Number of subjects: 7
Study 2547138 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Number of subjects: 7
Study 2547138 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration for 7 days
Number of subjects: 7
Study 766041 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) treatment at high plasma levels (less than 180 ng/ml)
Number of subjects: 24
Study 766041 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized reduction of plasma level among patients at high level
Number of subjects: 24
Study 766041 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation after 6 weeks of NT treatment
Number of subjects: 24
Study 766041 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects of NT treatment
Number of subjects: 24
Study 766041 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma range recommendation
Number of subjects: 24
Study 31634365 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral program (4-month duration)
Number of subjects: 50
Study 31634365 — intervention group
Group type: COMPARATOR
Intervention: Usual care wait-list
Number of subjects: 50
Study 27543565 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-nitride-oxide-coated bioactive stents (BAS)
Number of subjects: 827
Study 27543565 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 827
Study 24815999 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerolizer
Number of subjects: 98
Study 24815999 — intervention group
Group type: EXPERIMENTAL
Intervention: Diskus
Number of subjects: 98
Study 24815999 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler
Number of subjects: 98
Study 24815999 — intervention group
Group type: EXPERIMENTAL
Intervention: Easyhaler
Number of subjects: 98
Study 24815999 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall inhalation characteristics
Number of subjects: 98
Study 24815999 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall inhaled volumes
Number of subjects: 98
Study 23588939 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 186
Study 23588939 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine + hydroxychloroquine (triple therapy)
Number of subjects: 186
Study 23588939 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 186
Study 21508915 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multidisciplinary Back School program including brief education and active back exercises (BSG, N.=41)
Number of subjects: 74
Study 21508915 — intervention group
Group type: COMPARATOR
Intervention: Medical assistance (CG, N.=29)
Number of subjects: 74
Study 19854959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 40
Study 19854959 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation (ES)
Number of subjects: 40
Study 16913261 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid immunization
Number of subjects: 30
Study 16913261 — intervention group
Group type: EXPERIMENTAL
Intervention: PHA stimulation
Number of subjects: 30
Study 15799934 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair (ER)
Number of subjects: 187
Study 15799934 — intervention group
Group type: COMPARATOR
Intervention: Open repair (OR)
Number of subjects: 187
Study 10936835 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral microscopy
Number of subjects: 35
Study 10936835 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical examination
Number of subjects: 35
Study 9051544 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose etomidate (HET) 0.5 to 1.7 mg/kg titrated to an early burst suppression pattern
Number of subjects: 66
Study 9051544 — intervention group
Group type: COMPARATOR
Intervention: Low-dose etomidate (LET) 0.4 to 0.6 mg/kg titrated to an EEG spectral edge frequency (SEF) of 10 to 12 Hz
Number of subjects: 66
Study 9051544 — intervention group
Group type: COMPARATOR
Intervention: Thiopental sodium (THIO) 3 to 6 mg/kg titrated to the same EEG endpoint
Number of subjects: 66
Study 8119064 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-duration adjuvant chemotherapy
Number of subjects: 0
Study 8119064 — intervention group
Group type: COMPARATOR
Intervention: Short-duration chemotherapy
Number of subjects: 0
Study 3494257 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral auricular transcutaneous electrical nerve stimulation
Number of subjects: 60
Study 3494257 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral auricular transcutaneous electrical nerve stimulation
Number of subjects: 60
Study 3494257 — intervention group
Group type: COMPARATOR
Intervention: Control group (no auricular stimulation)
Number of subjects: 60
Study 29481630 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinflunine 280 mg/m2 intravenously every 3 weeks (q3w)
Number of subjects: 594
Study 29481630 — intervention group
Group type: COMPARATOR
Intervention: Alkylating agent (AA) monotherapy q3w
Number of subjects: 594
Study 27377418 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight sessions of ABMT
Number of subjects: 719
Study 27377418 — intervention group
Group type: EXPERIMENTAL
Intervention: Four sessions of ABMT
Number of subjects: 719
Study 27377418 — intervention group
Group type: EXPERIMENTAL
Intervention: Four sessions of ACT
Number of subjects: 719
Study 27377418 — intervention group
Group type: COMPARATOR
Intervention: No-training control
Number of subjects: 719
Study 24827034 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose posaconazole (100 mg twice daily)
Number of subjects: 78
Study 24827034 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose posaconazole (400 mg twice daily)
Number of subjects: 78
Study 24827034 — intervention group
Group type: COMPARATOR
Intervention: Benznidazole (150 mg twice daily)
Number of subjects: 78
Study 21917191 — intervention group
Group type: EXPERIMENTAL
Intervention: 34 g fish pâté (n 44)
Number of subjects: 159
Study 21917191 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml fruit juice (n 38)
Number of subjects: 159
Study 21917191 — intervention group
Group type: EXPERIMENTAL
Intervention: three capsules of concentrated fish oil (n 40)
Number of subjects: 159
Study 21917191 — intervention group
Group type: COMPARATOR
Intervention: Control group (n 37)
Number of subjects: 159
Study 20092584 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus regimen with insulin glargine and insulin glulisine
Number of subjects: 310
Study 20092584 — intervention group
Group type: COMPARATOR
Intervention: Premixed insulin regimen
Number of subjects: 310
Study 18312059 — intervention group
Group type: EXPERIMENTAL
Intervention: High maternal fetal attachment (measured by MAAS)
Number of subjects: 129
Study 18312059 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal relationship dissatisfaction (measured by DAS)
Number of subjects: 129
Study 18312059 — intervention group
Group type: EXPERIMENTAL
Intervention: Incompetent cervix (obstetric complication)
Number of subjects: 129
Study 18312059 — intervention group
Group type: EXPERIMENTAL
Intervention: EPDS score of 11 or greater
Number of subjects: 129
Study 18312059 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM-IV criteria for major depressive disorder
Number of subjects: 129
Study 16424842 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐atrial cannulation (group A)
Number of subjects: 120
Study 16424842 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐atrial cannulation with intraoperative hemofiltration (group B)
Number of subjects: 120
Study 16424842 — intervention group
Group type: COMPARATOR
Intervention: Bicaval cannulation (group C)
Number of subjects: 120
Study 16424842 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 12719782 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg daily
Number of subjects: 43
Study 12719782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 11056099 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-phase pulse duration of 1 ms
Number of subjects: 36
Study 11056099 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-phase pulse duration from 2 to 18 ms
Number of subjects: 36
Study 11056099 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2 energy
Number of subjects: 36
Study 11056099 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized average current during phase 2
Number of subjects: 36
Study 8853248 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg daily
Number of subjects: 8
Study 8853248 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg daily plus repeated laser photocoagulation
Number of subjects: 8
Study 1847704 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 0
Study 1847704 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 75 mg
Number of subjects: 0
Study 1847704 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril with Dexamethasone (DXM) 25 mg
Number of subjects: 0
Study 1847704 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril with Dexamethasone (DXM) 75 mg
Number of subjects: 0
Study 1847704 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM)
Number of subjects: 0
Study 1847704 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin with captopril
Number of subjects: 0
Study 1847704 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 0
Study 6294263 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 75 mg/kg
Number of subjects: 17
Study 6294263 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 50 mg/kg
Number of subjects: 17
Study 6294263 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (both dosages)
Number of subjects: 17
Study 29740015 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (ALA) + sodium ferrous citrate (SFC) supplementation
Number of subjects: 9
Study 29740015 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 9
Study 26654212 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy for perinatal depression (MBCT-PD)
Number of subjects: 86
Study 26654212 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 86
Study 25113509 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mL of 0.33% ropivacaine and normal saline with epinephrine
Number of subjects: 50
Study 25113509 — intervention group
Group type: COMPARATOR
Intervention: Normal saline with epinephrine
Number of subjects: 50
Study 22455835 — intervention group
Group type: EXPERIMENTAL
Intervention: OCD treatment response
Number of subjects: 76
Study 21595143 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopedic treatment including Minimal invasive Therapy (MIT)
Number of subjects: 0
Study 21595143 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturopathic 'complex'-treatment
Number of subjects: 0
Study 18814453 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI
Number of subjects: 1076
Study 18814453 — intervention group
Group type: COMPARATOR
Intervention: Budesonide pMDI
Number of subjects: 1076
Study 18814453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1076
Study 16155268 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g resistant starch/d
Number of subjects: 10
Study 12947272 — intervention group
Group type: EXPERIMENTAL
Intervention: New strategy using transcutaneous oxygen pressure (tcPo(2)) and toe blood pressure (TP) measurements
Number of subjects: 96
Study 12947272 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy using clinical judgment and ankle pressure
Number of subjects: 96
Study 10814606 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ATP infusion (75 microg.min(‐1).kg(‐1))
Number of subjects: 12
Study 10814606 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ATP infusion (37-50 microg.min(‐1).kg(‐1))
Number of subjects: 12
Study 10814606 — intervention group
Group type: COMPARATOR
Intervention: Control NSCLC patients (N=13) and healthy subjects (N=11)
Number of subjects: 12
Study 9015906 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg o.m. plus clarithromycin 500 mg t.i.d. for 14 days (group L30)
Number of subjects: 26
Study 9015906 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.i.d. plus clarithromycin 500 mg t.i.d. for 14 days (group L60)
Number of subjects: 26
Study 9015906 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (L30 and L60)
Number of subjects: 26
Study 2056290 — intervention group
Group type: EXPERIMENTAL
Intervention: Home air-fluidized bed therapy
Number of subjects: 112
Study 2056290 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 112
Study 6616404 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC plus hyperthermia (42 degrees C)
Number of subjects: 53
Study 6616404 — intervention group
Group type: COMPARATOR
Intervention: DTIC at 37 degrees C
Number of subjects: 53
Study 6616404 — intervention group
Group type: COMPARATOR
Intervention: Hyperthermia alone (42 degrees C)
Number of subjects: 53
Study 6616404 — intervention group
Group type: COMPARATOR
Intervention: DTIC at 42 degrees C
Number of subjects: 53
Study 6616404 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC plus hyperthermia
Number of subjects: 53
Study 31111509 — intervention group
Group type: EXPERIMENTAL
Intervention: Two €5 incentives (at the beginning and at the end of screening)
Number of subjects: 1652
Study 31111509 — intervention group
Group type: COMPARATOR
Intervention: One €10 incentive (upon completion of screening)
Number of subjects: 1652
Study 28539177 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens/bazedoxifene (CE/BZA)
Number of subjects: 664
Study 28539177 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical parameters (vaginal pH, parabasal/superficial cells)
Number of subjects: 664
Study 27284561 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea chewing gum
Number of subjects: 45
Study 27284561 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 45
Study 25060107 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN) protocol
Number of subjects: 0
Study 25060107 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 19294953 — intervention group
Group type: COMPARATOR
Intervention: School-based intervention program (N = 41) consisting of four 50-minute classes over a 4-week period educating on healthy lifestyle based on cognitive-behavior therapy framework.
Number of subjects: 81
Study 19294953 — intervention group
Group type: COMPARATOR
Intervention: Control class (CAU, N = 40)
Number of subjects: 81
Study 19294953 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention program for adolescents with delayed sleep timing (DST; Program, N = 21)
Number of subjects: 81
Study 19294953 — intervention group
Group type: COMPARATOR
Intervention: Control class for adolescents with delayed sleep timing (DST; CAU, N = 15)
Number of subjects: 81
Study 17466242 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral hop test
Number of subjects: 29
Study 17466242 — intervention group
Group type: COMPARATOR
Intervention: Forward hop test
Number of subjects: 29
Study 11008725 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% GTN ointment
Number of subjects: 37
Study 11008725 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg nitroglycerin patch
Number of subjects: 37
Study 11008725 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment (Control group C)
Number of subjects: 37
Study 9366699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (adults, 0.5 mL; children, 0.25 mL) twice daily for 10 days
Number of subjects: 601
Study 9366699 — intervention group
Group type: COMPARATOR
Intervention: Cortisporin (adults, 0.2 mL; children, 0.15 mL) 4 times daily for 10 days
Number of subjects: 601
Study 1531118 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous maintenance of anaesthesia with an infusion of propofol and increments of alfentanil (Group P)
Number of subjects: 80
Study 1531118 — intervention group
Group type: COMPARATOR
Intervention: Inhalational maintenance of anaesthesia with nitrous oxide and enflurane (Group E)
Number of subjects: 80
Study 3158128 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (2 mg/min intravenous infusion following an initial bolus of 200 mg)
Number of subjects: 49
Study 3158128 — intervention group
Group type: COMPARATOR
Intervention: No lidocaine
Number of subjects: 49
Study 3158128 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine and No lidocaine
Number of subjects: 49
Study 31705526 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg by subcutaneous injection
Number of subjects: 119
Study 31705526 — intervention group
Group type: COMPARATOR
Intervention: Fumaric acid esters (FAE)
Number of subjects: 119
Study 29621660 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar perception training using a hardness discrimination task
Number of subjects: 62
Study 29621660 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar perception training
Number of subjects: 62
Study 29621660 — intervention group
Group type: COMPARATOR
Intervention: Control group performing the same task without hardness discrimination
Number of subjects: 62
Study 26453914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AsA) 500 mg; α-tocopherol 300 IU
Number of subjects: 8
Study 26453914 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study 24885600 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin C infusion plus oral administration of vitamin E during angioplasty, followed by oral doses of vitamins C and E for 84 days
Number of subjects: 134
Study 24885600 — intervention group
Group type: COMPARATOR
Intervention: Placebo during angioplasty, followed by placebo for 84 days
Number of subjects: 134
Study 24885600 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin C infusion plus oral administration of vitamin E
Number of subjects: 134
Study 24885600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 22228118 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (PTX)
Number of subjects: 27
Study 22228118 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 27
Study 20413269 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction osteogenesis (DO)
Number of subjects: 21
Study 20413269 — intervention group
Group type: COMPARATOR
Intervention: Conventional orthognathic surgery (CO)
Number of subjects: 21
Study 18606481 — intervention group
Group type: EXPERIMENTAL
Intervention: 9vPnC‐MnCC (CRM197‐conjugated pneumococcal serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F and meningococcal C polysaccharides) given in three doses (3, 4, and 5 months)
Number of subjects: 223
Study 18606481 — intervention group
Group type: COMPARATOR
Intervention: 9vPnC‐MnCC (CRM197‐conjugated pneumococcal serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F and meningococcal C polysaccharides) given in two doses (3 and 5 months)
Number of subjects: 223
Study 15811481 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg TID
Number of subjects: 51
Study 15811481 — intervention group
Group type: COMPARATOR
Intervention: Placebo TID
Number of subjects: 51
Study 12093340 — intervention group
Group type: EXPERIMENTAL
Intervention: Promogran (n = 138)
Number of subjects: 276
Study 12093340 — intervention group
Group type: COMPARATOR
Intervention: Moistened gauze (control group; n = 138)
Number of subjects: 276
Study 12093340 — intervention group
Group type: EXPERIMENTAL
Intervention: Promogran (n = 95)
Number of subjects: 276
Study 12093340 — intervention group
Group type: COMPARATOR
Intervention: Moistened gauze (control group; n = 89)
Number of subjects: 276
Study 12093340 — intervention group
Group type: COMPARATOR
Intervention: Moistened gauze (control group; n = 49)
Number of subjects: 276
Study 12093340 — intervention group
Group type: EXPERIMENTAL
Intervention: Promogran (n = 43)
Number of subjects: 276